Início › Mieloma Múltiplo › Indiana › Indianapolis
Ensaios clínicos de Mieloma Múltiplo em Indianapolis, IN
13 estudos para Mieloma Múltiplo estão buscando participantes em locais em Indianapolis e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RecrutandoFase 3
- Franciscan Health, Indianapolis
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RecrutandoFase 4
- Indiana University, Indianapolis
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecrutandoFase 2
- Community Health Network (The University of Texas MD Anderson Cancer Center), Indianapolis
Collection of Tissue Samples for Cancer Research
RecrutandoEstudo observacional
- Indiana University - Purdue, Indianapolis
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RecrutandoFase 3
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RecrutandoFase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- IU Health Methodist Hospital, Indianapolis
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
RecrutandoFase 1
- Indiana University, Indianapolis
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RecrutandoFase 2
- Indiana University Health, Indianapolis
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecrutandoFase 1
- Franciscan St. Francis Health /ID# 280928, Indianapolis
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
RecrutandoFase 1
- Indiana University Health Simon Cancer Center, Indianapolis
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RecrutandoFase 1/2
- Community Health Network, Indianapolis
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
RecrutandoFase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Saint Catherine Hospital, Indianapolis
The Indiana Myeloma Registry
RecrutandoEstudo observacional
- Indiana University Simon Cancer Center, Indianapolis
Ensaios de Mieloma Múltiplo em outras cidades
- New York City, NY60 estudos
- Boston, MA42 estudos
- Atlanta, GA41 estudos
- Houston, TX38 estudos
- Durham, NC37 estudos
- Nashville, TN32 estudos
- Denver, CO27 estudos
- Rochester, MN24 estudos
- St. Louis, MO24 estudos
- Columbus, OH24 estudos
- Baldwin Park, CA23 estudos
- Chicago, IL22 estudos
Outros estudos em Indianapolis
- Câncer de Pulmão de Não Pequenas Células32 estudos
- Câncer (todos os tipos)24 estudos
- Insuficiência Cardíaca23 estudos
- Câncer de Mama20 estudos
- Obesidade20 estudos
- Câncer Metastático19 estudos
- Câncer Colorretal18 estudos
- Câncer de Ovário17 estudos
- Câncer de Pulmão16 estudos
- Doença Cardiovascular16 estudos
- Diabetes Tipo 114 estudos
- Câncer Endometrial14 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.